During an advisory committee meeting for MPS I, Mr. Srivastava saw the passion and drive of MPS families to get a treatment made him realize the high odds these families face when their loved ones have rare disorders. By joining Ultragenyx, Mr. Srivastava is championing their fight to develop treatments for these underserved diseases. With more than 10 years of project and portfolio management experience from research to commercialization stage programs, Mr. Srivastava joined Ultragenyx in August 2011 and serves as Vice President, Program and Portfolio Management, overseeing the program development activities for the company. Mr. Srivastava’s experience and background includes over 20 years in the pharmaceutical and biotechnology industry, specifically focused on drug development in neurosciences and metabolic disorder therapeutic area including rare genetic disorders. Before joining Ultragenyx, Mr. Srivastava was Senior Director, Portfolio and Project Management at Elan/Janssen Alzheimer Immunotherapy, a position he held from 2008 until 2011. He was also Director, Global Program Manager, Diabetes at Amgen from 2005 to 2008 and Director, Program Management from 2003 to 2005 at BioMarin Pharmaceutical Inc. Mr. Srivastava holds a B.S. in Pharmacy from Banaras Hindu University, a M.S. in Medicinal Chemistry from St. Johns University and a M.A.S. in Management from Johns Hopkins University.